Chronic Kidney Disease Drugs Market: CKD Drug Industry Outlook, Key Players, Growth Drivers, Scope, Trends, Share, Size, Forecast Period 2017-2025

Chronic Kidney Disease Drugs Market Outlook 2017-2025

Kidneys have vital role in discarding the waste from body, blood regulation and mineral homeostasis. Dysfunction of the kidney leads to chronic kidney disease and has adverse impact on rest of the body. The factors such as increasing geriatric population, rise in number of chronic kidney disease cases and prevalence of other disease in body (such as diabetes, high blood pressure, smoking, obesity and others) that risk the increase of chronic kidney disease (CKD), tends to drive the global chronic kidney disease drugs market. In the United States nearly 20 million people are suffering from kidney disorders and 600,000 have kidney failure. Whereas in Brazil, 10 million people are identified to suffer from renal disorders and this incidence is growing at a rate of 10.0% every year, which is thus inducing the demand for chronic kidney disease drugs.

In current scenario, there are no drugs/medications that can cure or reverse the effect of CKD but by controlling and curing other diseases such as high blood pressure, diabetes, anemia and others can help to treat the symptoms. Various pharmaceutical companies are researching to find drugs and better treatment process of CKD. One such example is Novadiol, a pharmaceutical company, is undergoing the clinical trials of Dendocrin to treat secondary hyperparathyroidism (SHPT) in stage 3 and 4 CKD patients.

Our Global Chronic Kidney Disease Drugs Market can be segmented on the following basis:

Based on Drug Class

• ACE Inhibitors
• Calcium Channel Blockers
• Beta Blockers
• Angiotensin-II Receptor Blockers
• Diuretics
• Others (Erythropoiesis – stimulating Agents (ESAs))

Based on Distribution Channel 

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on Geography 

• North America (U.S. & Canada)  Chronic Kidney Disease Drugs Market {Market Share (%), Market Size (USD Billion)}
• Latin America (Brazil, Mexico & Rest Of Latin America)  Chronic Kidney Disease Drugs Market {Market Share (%), Market Size (USD Billion)}
• Europe (The U.K., Germany, France, Italy, Hungary, Spain, Poland, Sweden & Roe)  Chronic Kidney Disease Drugs Market {Market Share (%), Market Size (USD Billion)}
• Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest Of Asia)  Chronic Kidney Disease Drugs Market {Market Share (%), Market Size (USD Billion)}
• Middle East & Africa (GCC, South Africa, North Africa, Romea) Chronic Kidney Disease Drugs Market {Market Share (%), Market Size (USD Billion)}

Global Chronic Kidney Disease Drugs Market Outlook comprises of the following data:

• Chronic kidney disease drugs market size (USD Billion) and compound annual growth rate (%), 2017-2025
• Chronic kidney disease drugs potential markets, major markets, opportunistic markets, growing markets (by region, countries), 2017-2018
• Chronic kidney disease drugs market size (USD Billion) and compound annual growth rate (%), by drug class, 2017-2025
• Chronic kidney disease drugs market size (USD Billion) and compound annual growth rate (%), by distribution channel, 2017-2025
• Chronic kidney disease drugs under pipeline, 2016-17
• Number of new cases diagnosed of chronic kidney disease, 2016-17
• Growth rate (%) of chronic kidney disease cases, by geography, 2016-17
• Competitors Analysis

As per the research, major etiology of CKD is hypertension (80.0%) presented in patients followed by diabetes (33.0%) and cardiovascular diseases (11.9%) patients. The incidences of hypertension is increasing across the world including developed and developing countries. Therefore, the countries with increasing rate of diseases have higher rate CKD cases amounting to rise in demand of CKD drugs. The pharmaceutical companies and distribution companies have high growth opportunities in terms of supply of CKD drugs in the regions with rise in number of cases that are causing CKD, such as North America & Latin America.

Some of the major players included in the chronic kidney disease drugs market report are: Amgen Inc., Pfizer Inc., AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Sanofi S.A., GlaxoSmithKline Plc, Kissei Pharmaceutical Co. Ltd., AbbVie Inc., and Keryx Biopharmaceuticals Inc.